Kyowa Kirin gives Parkinson's drug another shot under SPA
This article was originally published in Scrip
Executive Summary
Despite a long and troubled development history, Kyowa Hakko Kirin continues to believe in the therapeutic value of its Parkinson's disease drug istradefylline, and has just started a new international Phase III program with the first-in-class oral adenosine A2A receptor antagonist with an eye on trying again for a US approval.
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.